progress
fight
malaria
achiev
increas
deploy
insecticidetr
bednet
artemisinin
combin
therapi
act
led
signific
reduct
diseas
burden
mani
malariaendem
countri
seneg
malaria
major
diseas
mani
year
account
outpati
consult
health
care
servic
introduct
rapid
diagnost
test
rdt
countri
contribut
better
document
malaria
case
result
reduct
antimalari
consumpt
rdt
improv
target
antimalari
drug
compar
test
bacteri
viral
diseas
pathogen
known
lead
caus
febril
ill
thu
patient
neg
malaria
rdt
manag
presumpt
mani
set
mani
febril
patient
may
prescrib
broad
spectrum
antibiot
context
declin
malaria
report
mani
african
countri
situat
lead
occurr
spread
antibiot
resist
well
poor
manag
febril
ill
thu
appropri
treatment
guidelin
need
achiev
better
understand
epidemiolog
nonmalaria
febril
ill
requir
prospect
studi
conduct
depart
medic
parasitolog
keur
rural
area
malaria
sentinel
site
central
part
seneg
reveal
febril
ill
among
outpati
neg
malaria
rdt
caus
acut
respiratori
infect
tine
et
al
unpublish
howev
studi
mainli
syndromicbas
diseas
surveil
approach
limit
biolog
investig
pathogen
identif
better
understand
pathogen
distribut
frequenc
acut
respiratori
tract
infect
improv
current
treatment
guidelin
help
shape
prevent
strategi
relat
diseas
studi
conduct
africa
identifi
respiratori
tract
infect
due
streptococcu
pneumonia
main
caus
nonmalaria
febril
ill
among
caus
typhoid
fever
urinari
tract
infect
parasit
infect
malaria
although
sever
studi
show
import
acut
respiratori
infect
ari
febril
ill
occurr
conduct
among
adult
patient
howev
understand
ari
transmiss
dynam
may
requir
addit
investig
among
higher
age
group
popul
inde
rout
transmiss
ari
still
unclear
look
pathogen
distribut
across
agegroup
becom
crucial
better
understand
pathogen
reservoir
especi
rural
set
high
burden
ari
central
part
seneg
meantim
previou
studi
focus
bacteri
ari
includ
assess
viral
caus
like
influenza
known
present
agegroup
provid
first
insight
import
gap
conduct
pilot
studi
seneg
explor
pathogen
commun
nasopharyng
tract
among
individu
ari
rural
primari
health
care
unit
includ
age
group
target
bacteria
virus
studi
carri
rural
area
keur
malaria
sentinel
site
locat
central
part
seneg
km
capit
citi
dakar
area
keur
cover
villag
health
post
provid
mainli
primari
care
keur
health
post
lamaram
health
post
head
nurs
demograph
surveil
system
dss
go
within
villag
total
popul
size
inhabit
cross
section
studi
carri
august
decemb
children
adult
attend
keur
health
post
symptom
suggest
acut
respiratori
infect
accord
imci
guidelin
screen
health
post
staff
elig
elig
particip
sent
research
team
enrol
studi
consent
particip
particip
previous
screen
respiratori
tract
infect
within
studi
period
patient
sever
ill
exclud
elig
particip
recruit
use
consecut
sampl
method
code
given
enrol
particip
physician
examin
particip
prior
biolog
assess
includ
nasopharyng
swab
collect
pcr
analysi
patient
interview
directli
determin
sociodemograph
characterist
patient
medic
histori
vaccin
statu
use
standard
questionnair
children
inform
obtain
mother
care
taker
enrol
studi
particip
pair
nose
throat
swab
collect
pathogen
detect
symptom
present
particip
day
survey
well
data
obtain
interview
biolog
investig
assign
case
report
form
crf
sampl
collect
studi
physician
use
steril
nylon
flock
swab
place
viral
transport
medium
bd
univers
viral
label
transport
ice
pasteur
institut
dakar
process
storag
sampl
nucleic
acid
extract
use
qiamp
viral
kit
accord
manufactur
instruct
pathogen
detect
perform
use
fast
track
diagnost
kit
ftd
respiratori
pathogen
kit
luxembourg
multiplex
pcr
essay
design
detect
pathogen
kit
present
tube
multiplex
pcr
detect
differ
pathogen
first
tube
influenza
influenza
b
influenza
human
rhinoviru
ii
second
tube
coronaviru
coronaviru
coronaviru
coronaviru
iii
third
tube
parainfluenza
parainfluenza
parainfluenza
intern
control
fourth
tube
parainfluenza
human
metapneumoviru
ab
bocaviru
mycoplasma
pneumonia
v
fifth
tube
respiratori
syncyti
virus
ab
adenoviru
enteroviru
parechoviru
vi
sixth
tube
chlamydia
pneumonia
streptococcu
pneumonia
haemophilu
influenza
type
b
staphylococcu
aureu
multiplex
realtim
pcr
ftd
assay
perform
abi
fast
instrument
life
technolog
usa
describ
elsewer
pcr
programm
follow
min
min
cycl
sampl
size
assumpt
particip
sampl
studi
power
provid
estim
pathogen
precis
assum
morbid
relat
acut
respiratori
infect
among
febril
outpati
temperatur
seen
health
post
tine
et
al
unpublish
alpha
two
side
data
enter
excel
softwar
analys
conduct
use
stata
packag
statacorp
texa
categor
data
percentag
use
assess
frequenc
outcom
confid
interv
continu
data
mean
standard
deviat
use
describ
normal
distribut
variabl
median
rang
data
characterist
particip
includ
studi
tabul
proport
compar
use
chi
squar
test
fisher
exact
test
appropri
univari
analysi
assess
effect
age
pathogen
distribut
multivari
logist
regress
done
adjust
covari
studi
period
final
model
adjust
odd
ratio
deriv
confid
interv
model
valid
test
use
hosmerlemeshow
good
fit
test
perform
final
model
assess
area
curv
akaik
bayesian
inform
criterion
addit
test
multicolinear
variabl
done
use
varianc
inflat
factor
signific
level
differ
test
two
side
particip
studi
strictli
voluntari
patient
refus
enrol
includ
studi
sign
inform
consent
obtain
elig
particip
prior
investig
minor
particip
age
year
inform
consent
obtain
parent
children
legal
repres
prior
enrol
ensur
confidenti
inform
collect
studi
analys
use
particip
identif
code
studi
protocol
studi
relat
document
crf
inform
consent
form
approv
senegales
nation
ethic
committe
conseil
nation
ethiqu
et
de
recherch
en
msasdprscner
du
mai
among
patient
consult
health
post
sign
suggest
respiratori
infect
fulfil
defin
inclus
criteria
enrol
studi
major
sampl
collect
among
year
agegroup
also
repres
affect
agegroup
due
low
number
sampl
year
sampl
year
sampl
aggreg
age
group
uniqu
agegroup
year
subsequ
analys
tabl
among
sampl
least
one
pathogen
identifi
sampl
frequent
pathogen
identifi
streptococcu
pneumonia
follow
staphylococcu
aureu
rhinoviru
fig
overal
particip
found
one
viral
speci
patient
infect
least
virus
proport
patient
coinfect
virus
patient
one
bacteri
speci
repres
patient
bacteri
speci
total
patient
found
least
bacteria
viru
time
tabl
highest
number
pathogen
detect
among
year
age
group
pathogen
mainli
repres
streptococcu
pneumonia
rhinoviru
year
staphylococcu
aureu
year
among
patient
age
year
main
pathogen
detect
nasopharyng
level
rhinoviru
staphylococcu
aureu
streptococcu
pneumonia
found
age
group
higher
frequenc
among
infant
children
ie
also
identifi
among
patient
age
year
frequenc
similarli
rhinoviru
detect
age
group
lower
proport
among
year
old
agegroup
pathogen
thu
circul
age
group
contrast
human
respiratori
syncyti
viru
detect
among
less
year
old
agegroup
major
influenza
ab
coronaviru
detect
year
old
age
group
rest
pathogen
detect
low
level
agegroup
distribut
identifi
pathogen
age
group
describ
tabl
month
sampl
provid
new
insight
tempor
dynam
pathogen
streptococcu
pneumonia
detect
similar
proport
month
remain
major
pathogen
detect
fig
major
human
respiratori
syncyti
viru
detect
august
decreas
septemb
octob
respiratori
syncyti
viru
found
month
novemb
decemb
staphylococcu
aureu
influenza
viru
ab
increas
septemb
decreas
rest
year
rhinovirus
detect
low
level
august
septemb
frequenc
increas
octob
novemb
decreas
decemb
final
coronaviru
detect
octob
increas
continu
decemb
tempor
distribut
show
trend
success
pathogen
time
within
popul
overal
bacteri
pathogen
common
among
children
compar
viral
pathogen
signific
statist
differ
among
children
less
year
preval
differ
p
year
preval
differ
p
signific
differ
note
compar
frequenc
bacteri
versu
viral
pathogen
year
preval
differ
p
year
preval
differ
p
tabl
higher
frequenc
viral
pathogen
compar
bacteri
pathogen
note
month
august
preval
differ
p
month
septemb
novemb
decemb
bacteri
pathogen
predominantli
isol
compar
viru
p
valu
period
tabl
adjust
age
group
patient
less
like
carri
viral
infect
month
septemb
adjust
odd
ci
novemb
adjust
odd
ratio
ci
decemb
adjust
odd
ratio
ci
tabl
acut
respiratori
infect
usual
clinic
diagnosi
mani
primari
health
care
unit
seneg
diagnosi
approach
often
base
imci
guidelin
pilot
studi
conduct
assess
spectrum
frequenc
pathogen
respons
ari
use
highli
sensit
multiplex
rtpcr
techniqu
studi
reveal
high
posit
rate
viral
bacteri
pathogen
broad
spectrum
pathogen
detect
age
group
month
period
data
collect
provid
origin
pathogen
commun
studi
global
popul
streptococcu
pneumonia
main
pathogen
detect
remain
constantli
highli
present
month
studi
mainli
among
children
also
among
adult
suggest
nonneglig
perman
reservoir
pathogen
among
older
agegroup
observ
deserv
investig
sinc
suggest
adult
repres
import
fraction
streptococcu
pneumonia
reservoir
potenti
contribut
adult
transmiss
streptococcu
pneumonia
younger
children
need
investig
determin
whether
also
need
protect
unfortun
studi
could
assess
divers
differ
pneumococc
serotyp
order
determin
serotyp
variabl
across
agegroup
context
recent
introduct
pneumococc
conjug
senegales
immun
program
crucial
document
circul
serotyp
compar
vaccineserotyp
agegroup
help
gener
evid
impact
vaccin
pneumococc
serotyp
highest
divers
pathogen
detect
nasopharyng
swab
among
patient
sign
suggest
ari
observ
among
children
year
old
inde
five
children
remain
vulner
group
regard
ari
describ
studi
streptococcu
pneumonia
staphylococcu
aureu
rhinoviru
major
pathogen
detect
agegroup
contrast
respiratori
syncyti
viru
detect
year
old
except
adult
children
suggest
transmiss
rout
pathogen
among
specif
popul
group
month
studi
also
suggest
tempor
dynam
pathogen
differ
season
pattern
instanc
respiratori
syncyti
viru
observ
august
septemb
coronaviru
detect
octob
decemb
tempor
dynam
pathogen
need
investig
throughout
continu
surveil
system
sever
year
look
potenti
season
pathogen
establish
clear
tempor
dynam
pathogen
could
help
shape
treatment
practic
prevent
intervent
studi
present
caveat
first
limit
consist
length
studi
larg
enough
clearli
establish
season
nevertheless
pilot
studi
reveal
relev
trend
explor
consid
specif
pattern
pathogen
eg
human
respiratori
syncyti
viru
coronaviru
agegroup
distribut
pathogen
eg
streptococcu
pneumonia
vs
human
respiratori
syncyti
viru
better
understand
transmiss
dynam
studi
use
highli
sensit
multiplex
rtpcr
detect
pathogen
among
patient
sign
suggest
ari
howev
possibl
clearli
establish
identifi
pathogen
respons
observ
symptom
still
pathogen
circul
within
whole
popul
streptococcu
pneumonia
remain
major
pathogen
circul
age
group
month
studi
next
step
consist
determin
serotyp
circul
respons
ari
context
recent
introduct
pneumococc
vaccin
africa
immun
program
infant
receiv
vaccin
seroconvers
quick
perfectli
time
follow
evolut
pneumococc
serotyp
vaccin
pressur
whole
popul
streptococcu
pneumonia
carriag
among
adult
neglig
studi
highlight
need
investig
adult
role
streptococcu
pneumonia
transmiss
infant
first
pilot
studi
month
surveil
commun
level
includ
viru
bacteria
deserv
routin
implement
assess
spatial
tempor
dynam
pathogen
commun
nasopharyng
level
surveil
system
allow
improv
current
treatment
practic
may
contribut
reduc
antibiot
consumpt
public
health
program
need
commun
pathogen
overview
better
control
respiratori
infect
among
highrisk
group
coinfect
crucial
explor
better
understand
link
symptom
pathogen
abl
provid
appropri
treatment
guidelin
